Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The study of Mendelian diseases and the identification of their causative genes are of great significance in the field of genetics. The evaluation of the pathogenicity of genes and the total number of Mendelian disease genes are both important questions worth studying. However, very few studies have addressed these issues to date, so we attempt to answer them in this study. We calculated the gene pathogenicity prediction (GPP) score by a machine learning approach (random forest algorithm) to evaluate the pathogenicity of genes. When we applied the GPP score to the testing gene set, we obtained an accuracy of 80%, recall of 93% and area under the curve of 0.87. Our results estimated that a total of 10,384 protein-coding genes were Mendelian disease genes. Furthermore, we found the GPP score was positively correlated with the severity of disease. Our results indicate that GPP score may provide a robust and reliable guideline to predict the pathogenicity of protein-coding genes. To our knowledge, this is the first trial to estimate the total number of Mendelian disease genes.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00439-019-02021-9DOI Listing

Publication Analysis

Top Keywords

gpp score
16
mendelian disease
12
disease genes
12
gene pathogenicity
8
pathogenicity prediction
8
mendelian diseases
8
random forest
8
forest algorithm
8
genes
8
pathogenicity genes
8

Similar Publications

Background: Generalized Pustular Psoriasis (GPP) is a rare but severe form of psoriasis, characterized by flares involving the sudden spread of erythema with sterile pustules, crusting, and scaling.

Objective: The study aimed to assess both generic and dermatology-specific health-related quality of life (HRQoL) in patients with GPP across flare and non-flare stages in Malaysia.

Methods: The study was a multicenter cross-sectional study conducted among patients diagnosed with GPP attending the General Hospitals under the Ministry of Health, Malaysia, between May 15, 2024, and November 30, 2024.

View Article and Find Full Text PDF

Introduction: This study aimed to report bimekizumab (BKZ) efficacy and safety in Japanese patients with generalised pustular psoriasis (GPP) and erythrodermic psoriasis (EP).

Methods: Patients aged ≥ 18 years with plaque psoriasis, GPP, or EP received BKZ for 144 weeks; only results for GPP and EP reported here. All patients received BKZ 320 mg every 4 weeks (Q4W) at week 0, with dose adjustments for Q4W or Q8W at weeks 16 and 48, depending on Investigator's Global Assessment (IGA) 0/1 response.

View Article and Find Full Text PDF

Introduction: Generalized pustular psoriasis (GPP) is a chronic, systemic, neutrophilic inflammatory disease that significantly impacts patients' quality of life (QoL). A multinational panel of patients with GPP participated in surveys and interviews, with the aim to assess the impact of chronic symptoms and GPP flares on QoL and well-being, and to better understand the resources and support that patients need.

Methods: Patients (aged 18-65 years) with a confirmed diagnosis of GPP (> 1 month), who had experienced ≥ 1 flare in the past year and were receiving active treatment for GPP were recruited through databases and healthcare professionals (HCPs).

View Article and Find Full Text PDF

Background: Anhedonia is a core feature of major depressive disorder (MDD), yet the clinical burden in real-world settings is not well understood. This retrospective cohort study assessed depression symptoms and treatment patterns among patients with MDD with and without prominent anhedonia.

Methods: Patients with MDD were selected from a real-world dataset of electronic health records from mental health specialists and linked medical and pharmacy claims (OM1, Inc.

View Article and Find Full Text PDF

Introduction: The International Psoriasis Council (IPC) reclassified patients eligible for systemic therapy to include those with body surface area (BSA) > 10%, psoriasis lesions in high-impact areas, or failure of topical therapy. Risankizumab is an interleukin-23 inhibitor approved for the treatment of moderate-to-severe plaque psoriasis. This retrospective study evaluated the real-world effectiveness of risankizumab in patients with BSA 3-10% and patients meeting IPC systemic therapy criteria, addressing existing gaps in knowledge regarding its effectiveness in these patient groups.

View Article and Find Full Text PDF